Related references
Note: Only part of the references are listed.Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG82 b&c
M. Kyndi et al.
ACTA ONCOLOGICA (2008)
The need for advanced breast cancer treatment guidelines: Results of an internet-based survey
Andrew Wardley
BREAST (2008)
Serum TIMP-1 and response to the aromatase inhibitor letrozole versus tamoxifen in metastatic breast cancer
Allan Lipton et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial
Birgitte B. Rasmussen et al.
LANCET ONCOLOGY (2008)
Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer:: BIG 1-98
Giuseppe Viale et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays
Katrine L. Henriksen et al.
JOURNAL OF CLINICAL PATHOLOGY (2007)
The discovery and mechanism of action of letrozole
Ajay S. Bhatnagar
BREAST CANCER RESEARCH AND TREATMENT (2007)
Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer
Brian Z. Ring et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A multimarker model to predict outcome in tamoxifen-treated breast cancer patients
SP Linke et al.
CLINICAL CANCER RESEARCH (2006)
Profiling of estrogen up- and down-regulated gene expression in human breast cancer cells: Insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype
J Frasor et al.
ENDOCRINOLOGY (2003)
Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women:: Analysis of survival and update of efficacy from the international letrozole breast cancer group
H Mouridsen et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen
A Lipton et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases
VJ Bardou et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
T Sorlie et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
